Market Capitalization (Millions $) |
213 |
Shares
Outstanding (Millions) |
39 |
Employees |
2,191 |
Revenues (TTM) (Millions $) |
8 |
Net Income (TTM) (Millions $) |
-50 |
Cash Flow (TTM) (Millions $) |
-6 |
Capital Exp. (TTM) (Millions $) |
0 |
Scpharmaceuticals Inc
SCPharmaceuticals Inc. is a pharmaceutical company that specializes in the development of innovative, simple, and convenient therapies for patients with acute and chronic conditions that require frequent injections or infusions. The company was founded in 2013 and is headquartered in Burlington, Massachusetts, with additional locations in Rhode Island and California.
The primary goal of SCPharmaceuticals is to revolutionize the way patients receive medications by providing them with easy-to-use, portable, and cost-effective options that can be administered outside of traditional healthcare settings. The company's product portfolio includes the Furoscixe (furosemide injection) platform, which is a subcutaneous infusion system designed for patients who require diuretic therapy for heart failure.
Furoscixe is a portable and convenient infusion system that enables patients to self-administer furosemide at home, thereby reducing the need for repeated hospitalizations and improving patient outcomes. The product has demonstrated significant clinical benefits in multiple Phase III clinical trials, including reduced hospitalizations, improved quality of life, and a lower risk of adverse events.
SCPharmaceuticals is also developing other innovative products for the treatment of various conditions, including infectious diseases, metabolic disorders, and inflammatory diseases. The company's pipeline includes several promising candidates, such as the Antibiotic Site Infusion System (ASIS) platform, which is a novel, easy-to-use infusion system for delivering antimicrobial agents to patients with bacterial infections.
Overall, SCPharmaceuticals is dedicated to providing patients with effective, convenient, and affordable therapies that improve their quality of life and reduce the burden of chronic diseases. With its innovative products and commitment to patient-centered care, the company has become a leader in the field of subcutaneous drug delivery and is poised for continued growth and success in the years ahead.
Company Address: 25 Burlington Mall Road Burlington 1803 MA
Company Phone Number: 517-0730 Stock Exchange / Ticker: NASDAQ SCPH
SCPH is expected to report next financial results on March 21, 2024. |
|
|